📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 5 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Ouest-France · 26/02/2026
<a href="https://news.google.com/rss/articles/CBMirAJBVV95cUxQLXBidHhFeWJSV3dTR1kwcmtzSDExdlNER2s4LXFTUjFZTTRKdXNTUzRzSjB0SFBwT2VSMFMtODZUOXZsendTZE1JRnhvZGZ5cUUyY0hjak5RUWF2dXNTclNGbFoxSDJiSVVpZkFDTDQzX0NLTFhkZEY2SUJEYzRQYW8taWdUdVhpWGpReTFwUHd6VEt2RXhmMmFMc09qRXRycndUdVo0T0tiN3NveDlnbm5sdl9XMElocW
📰 Le Télégramme · 26/02/2026
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxQREZaZC03VHNrWFRtejFRejI0TXNTTFR5LXk3MVBwS0ZUTXpFNTZjRnRUN1FjX2JRMDhaRlJlYl9GY2RSWVFhS1Bfa3p0TW5hX3RQQmoxY0RxNlJCWjBtb3NqOThnMmlNVjYzM0YzOGE2MjZ1Nkoyb2NBb2g2VWFraWFKRUxKM0N0YUk0TWpqWUw0UUR1MmN0ZEJfUW9la0RPMERoTmpZNlZpTVRVN09mV3Q5eXE5ZHJxam
📰 Le Progrès · 30/08/2024
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNYmlyWW5udVFYNlowaUR4RDdJWm4xQ0h3RHk1aEFRSU1PNE1MblNYYVRPNWpWU0NUUC12SmxtdXhiM3RHSDhMUWhmOE94S1JrZGI2Ym5yN2lFUTNRdkczNllXVWRQYTNERFRUNW03V2VNNVFsbDVueGhlQXlEOTgzVlVhZzdvMnJEUlRobUxqb3EyZUwtRzZsQnY3Qm11YUNhTWx0UDZILTZKNVFCamdHaDQ4OGh6UlhleT
📰 Ouest-France · 19/09/2017
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFBtQjZfWk5Ta1ZiSnRTRDZqV21YWWZSTjB1cUJYV2RIOGtHYUo4d1dMTXVITU5IdGp2cmUzQTdhaWNvNjNMclI0MS1mVXExTTI3NUpSMmlzYTV3TFZVUVA2TUk5dHBvMGl2bUxQTjJwZVphc1k4dWNxalVHNGk0UQ?oc=5" target="_blank">Résultats élections municipales 2026 Hennebont [56700] :
📰 L'Alsace · 15/06/2012
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSjJMamhreXBoRWItUXh0alRfZG1zVFpud2U4UFdCMThxZmZvc1gwU1F3Nkx6UG8wRU5ENVF4ZXpqRzB2UW1hYlNqSlZ2UFBxYkprVHc1aGRDektHUEctRGZtaEVGNGQ3dWxBUmQzUkY1Ql9nWmJhaU5qTTQzaUJoSjFraS1WZFIxc00xOVRQaWNLX0d2X1FNZzk1bGZkbVVFX1ZUSl9XLXM?oc=5" target="_blank">
Bone · 2004
Arthritis research & therapy · 2005
AbstractThis study sought to evaluate the levels of mRNA expression and protein synthesis of MMP-13, cathepsin K, aggrecanase-1 (ADAMTS-4), aggrecanase-2 (ADAMTS-5) and 5-lipoxygenase (5-LOX) in cartilage in the experimental anterior cruciate ligament (ACL) dog model of osteoarthritis (OA), and to examine the effects of treatment with licofelone, a 5-lipoxygenase (LOX)/cyclooxygenase (COX) inhibitor, on the levels of these catabolic factors. Sectioning of the ACL of the right knee was performed in three experimental groups: group 1 received no active treatment (placebo group); and groups 2 and 3 received therapeutic concentrations of licofelone (2.5 or 5.0 mg/kg/day orally, respectively) for 8 weeks, beginning the day following surgery. A fourth group consisted of untreated dogs that were used as normal controls. Specimens of cartilage were selected from lesional areas of OA femoral condyles and tibial plateaus, and were processed for real-time quantitative PCR and immunohistochemical analyses. The levels of MMP-13, cathepsin K, ADAMTS-4, ADAMTS-5 and 5-LOX were found to be significantly increased in OA cartilage. Licofelone treatment decreased the levels of both mRNA expression and protein synthesis of the factors studied. Of note was the marked reduction in the level of 5-LOX gene expression. The effects of the drug were about the same at both tested dosages. In vivo treatment with therapeutic dosages of licofelone has been found to reduce the degradation of OA cartilage in experimental OA. This, coupled with the results of the present study, indicates that the effects of licofelone are mediated by the inhibition of the major cartilage catabolic pathways involved in the destruction of cartilage matrix macromolecules. Moreover, our findings also indicate the possible auto-regulation of 5-LOX gene expression by licofelone in OA cartilage.
Arthritis and rheumatism · 2005
AbstractObjectiveTo examine the in vivo effects of PD‐0200347, an α2δ ligand of voltage‐activated Ca2+ channels and a compound chemically related to pregabalin and gabapentin, on the development of cartilage structural changes in an experimental dog model of osteoarthritis (OA). The effects of PD‐0200347 on the major pathways involved in OA cartilage degradation, including matrix metalloproteinases (MMPs) and the inducible form of nitric oxide synthase (iNOS), were also studied.MethodsOA was surgically induced in dogs by sectioning the anterior cruciate ligament. OA dogs were randomly distributed into 3 groups and treated orally with either 1) placebo, 2) 15 mg/kg/day of PD‐0200347, or 3) 90 mg/kg/day of PD‐0200347. Dogs were killed 12 weeks after surgery. The severity of the lesions was scored macroscopically and histologically. Cartilage specimens from the femoral condyles and tibial plateaus were processed for RNA extraction and quantitative reverse transcription–polymerase chain reaction (RT‐PCR) or immunohistochemistry. Specific probes and antibodies were used to study the messenger RNA and protein levels of iNOS, MMP‐1, MMP‐3, and MMP‐13.ResultsNo clinical signs of drug toxicity were noted in the treated animals. Treatment with PD‐0200347 at both dosages tested (15 and 90 mg/kg/day) reduced the development of cartilage lesions. There was a reduction in the score of lesions, with a statistically significant (P = 0.01) difference when the highest dosage of the drug was administered. The reduction in the score was mainly related to a decrease in the surface size of the lesions. Quantitative RT‐PCR showed that PD‐0200347 significantly reduced the expression of MMP‐13, a key mediator in OA. Immunohistochemical analyses showed that treatment with PD‐0200347 significantly reduced the synthesis of all key OA mediators studied.ConclusionThis study demonstrated the efficacy of PD‐0200347 in reducing the progression of cartilage structural changes in a dog model of OA. It also showed that this effect is linked to the inhibition of the major pathophysiologic mediators responsible for cartilage degradation.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Arthritis and rheumatism · 2005 · Journal Article
Boileau C, Martel-Pelletier J, Brunet J, Tardif G, et al.
Arthritis research & therapy · 2005 · Comparative Study
Pelletier JP, Boileau C, Boily M, Brunet J, et al.
Bone · 2004 · Comparative Study
Pelletier JP, Boileau C, Brunet J, Boily M, et al.
Laval medical · 1953 · Journal Article
THIBODEAU R, NADEAU G, BRUNET J
Rheumatology (Oxford, England) · 2022 · Journal Article
Daumas A, Magalon J, Jouve E, Casanova D, et al.
The Journal of bone and joint surgery. British volume · 2000 · Journal Article
Brunet JA
Allergie et immunologie · 2001 · Journal Article
Brunet JL, Liaudet AP, Later R, Peyramond D, et al.